You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

EMA accepts Mundipharma’s application for candidiasis drug rezafungin

The European Medicines Agency (EMA) has accepted Mundipharma’s marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adults.